Macrobian-Biotech was founded in May 2017 by Dr. Lars van der Heide and Prof. dr. Marten Smidt. Its primary goal is to perform pre-clinical research that leads to novel treatments for disorders that affect the midbrain dopamine system. The company is currently housed at the Amsterdam Science Park, the heart of academic excellence in the Netherlands.